Regeneron Pharmaceuticals Total Non-Operating Income/Expense 2010-2024 | REGN

Regeneron Pharmaceuticals total non-operating income/expense for the twelve months ending September 30, 2024 was $996M, a 540.93% increase year-over-year.

  • Regeneron Pharmaceuticals annual total non-operating income/expense for 2023 was $0.152B, a 26.94% increase from 2022.
  • Regeneron Pharmaceuticals annual total non-operating income/expense for 2022 was $0.12B, a 68.36% decline from 2021.
  • Regeneron Pharmaceuticals annual total non-operating income/expense for 2021 was $0.379B, a 62.1% increase from 2020.

Regeneron Pharmaceuticals Total Non-Operating Income/Expense 2010-2024 | REGN

  • Regeneron Pharmaceuticals annual total non-operating income/expense for 2023 was $0.152B, a 26.94% increase from 2022.
  • Regeneron Pharmaceuticals annual total non-operating income/expense for 2022 was $0.12B, a 68.36% decline from 2021.
  • Regeneron Pharmaceuticals annual total non-operating income/expense for 2021 was $0.379B, a 62.1% increase from 2020.